ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0089

The Risk Factors of Recurrence in Relapsing Polychondritis; A Study of 41 Cases

Tsuneyasu Yoshida1, Hajime Yoshifuji2, Mirei Shirakashi1, Koji Kitagori1, Shuji Akizuki2, Ran Nakashima1, Kosaku Murakami1, Motomu Hashimoto3, Masao Tanaka3 and Koichiro Ohmura1, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Kyoto, Japan, 2Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, 3Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan

Meeting: ACR Convergence 2020

Keywords: Cohort Study, glucocorticoids, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Relapsing polychondritis (RP) is a rare disease which causes inflammation in systemic cartilages. Although glucocorticoids (GC) and immunosuppressive drugs (IS) have been used, the recurrence rate remains high. It has been reported that tracheobronchial lesion is a poor prognostic factor, however, other risk factors have not been sufficiently investigated. We conducted a retrospective study on risk factors for recurrence.

Methods: We selected patients who had been diagnosed as RP according to Damiani’s or Michet’s criteria and treated at Kyoto University Hospital between 2001 and 2020. We excluded the patients with observation period less than one year and patients who had been taking oral GC for the treatment of other diseases at the time of the diagnosis of RP. Recurrence was defined as 1) aggravation of any symptoms or 2) worsening of the laboratory data that led to intensified treatments.

Results: Forty-one patients were extracted. The mean age at onset was 50±18 years, and the rate of women was 58.5%. The duration of observation was 6.6±5.8 years and the time from onset to diagnosis was 433±903 days. Of the 41 patients, 30 underwent recurrences (73.2%). The number of recurrences was 73 in total and 2.4 per person in average. The median time to the initial recurrence was 202 days. The median dose of prednisolone (PSL) at the first relapse was 10 mg.

The patients were divided into recurrence and non-recurrence groups. In the recurrence group, the patients with tracheobronchial lesion as an initial symptom were more frequent (p=0.0108), and the activity index (RPDAI) (p=0.0178), serum CRP (p=0.0030) and IgG (p=0.0347) levels at the time of onset were higher than in non-recurrence group.

We next compared initial PSL monotherapy group (n=23) with initial PSL plus IS group (n=11) and found that the latter group showed significantly higher recurrence free survival rate at 1 year after initial treatment (p=0.0341, Figure 1).

Conclusion: We found tracheobronchial lesion, high RPDAI, high serum CRP and IgG as risk factors for recurrence. It was suggested that initial combination of PSL with IS could prolong recurrence-free period.

Recurrence free survival rate between prednisolone only therapy and prednisolone combinded with Immunosuppressant.


Disclosure: T. Yoshida, None; H. Yoshifuji, None; M. Shirakashi, None; K. Kitagori, GlaxoSmithKline, 2; S. Akizuki, None; R. Nakashima, None; K. Murakami, None; M. Hashimoto, None; M. Tanaka, UCB Japan Co., Ltd., 1, 2, AbbVie GK, 1, Asahi Kasei Pharma Corp., 1, 2, Astellas Pharma Inc., 1, Ayumi Pharmaceutical Corp., 1, 2, Bristol-Myers Squibb, 1, Chugai Pharmaceutical Co., Ltd., 1, 2, Eisai Co., Ltd., 1, Eli Lilly Japan K.K., 1, Pfizer Inc., 1, Janssen Pharmaceutical K.K., 1, Mitsubishi Tanabe Pharma Corp., 1, 2, Novartis Pharma K.K., 1, Taisho Pharma Co., Ltd., 1; K. Ohmura, Sanofi, 2, 8, Tanabe-Mitsubishi, 2, Chugai, 2, Astellas, 2, Eisai, 2, Abbvie, 2, 8.

To cite this abstract in AMA style:

Yoshida T, Yoshifuji H, Shirakashi M, Kitagori K, Akizuki S, Nakashima R, Murakami K, Hashimoto M, Tanaka M, Ohmura K. The Risk Factors of Recurrence in Relapsing Polychondritis; A Study of 41 Cases [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-risk-factors-of-recurrence-in-relapsing-polychondritis-a-study-of-41-cases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risk-factors-of-recurrence-in-relapsing-polychondritis-a-study-of-41-cases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology